Islet allografts expressing a PD‐L1 and IDO fusion protein evade immune rejection and reverse preexisting diabetes in immunocompetent mice without systemic immunosuppression

Allogeneic islet transplantation is a promising experimental therapy for poorly controlled diabetes. Despite pharmacological immunosuppression, long‐term islet engraftment remains elusive. Here, we designed a synthetic fusion transgene coupling PD‐L1 and indoleamine dioxygenase [hereafter PIDO] whos...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Pradyut K., Das, Rahul, Drow, Travis, Nylen, Emily A., de Souza, Arnaldo Henrique, Wang, Zunyi, Wood, Michael W., Davis, Dawn B., Bjorling, Dale E., Galipeau, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804298/
https://www.ncbi.nlm.nih.gov/pubmed/35897156
http://dx.doi.org/10.1111/ajt.17162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804298/
https://www.ncbi.nlm.nih.gov/pubmed/35897156
http://dx.doi.org/10.1111/ajt.17162

Ejemplares similares